What are the Pfizer SSGJ-707 deal terms?
On May 19, 2025, Pfizer announced a license for 3SBio’s SSGJ-707 with a $1.25 billion upfront payment and up to $4.8 billion in development, regulatory and commercial milestones. Those components sum to a potential $6.05 billion before royalties; the separately announced $100 million equity investment is not part of that licensing total.
| Measure | Reported result | Basis |
|---|---|---|
| Upfront payment | $1.25 billion | License consideration |
| Potential milestones | Up to $4.8 billion | Conditional development, regulatory and commercial payments |
| Potential license total | Up to $6.05 billion | Calculated: upfront plus maximum milestones |
| Separate equity investment | $100 million | Excluded from the license total |
Ivonescimab after the FDA letter
On November 15, 2026 (U.S. time), Summit Therapeutics announced that it had received an FDA complete response letter for Akeso’s ivonescimab. In the 438-patient HARMONi trial, primary overall survival yielded p=0.057 against a prespecified threshold of 0.0448; median overall survival was 16.8 months with ivonescimab plus chemotherapy versus 14.0 months with chemotherapy. The application could not be approved on the current data. Subsequent first-line lung cancer evidence will come from HARMONi-3 and HARMONi-7.
Sources
Read the full analysis
FDA Rejects Akeso’s Bispecific: PFS Was Not Enough — November 17, 2026